Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Physostigmine | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Physostigmine | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | Physostigmine | hsa00830 | Retinol metabolism | 1.56E-03 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Physostigmine | hsa04014 | Ras signaling pathway | 4.65E-02 | 3 | Q15311, P0DP23, P17612 | RALBP1, CALM1, PRKACA | More | | Physostigmine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Physostigmine | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Physostigmine | hsa04064 | NF-kappa B signaling pathway | 7.84E-04 | 15 | O00463, P14778, P01584, P01375, P19174, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, P19875, Q06643, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PLCG1, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CXCL2, LTB, CYLD | More | | Physostigmine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Physostigmine | hsa04114 | Oocyte meiosis | 2.15E-02 | 3 | P0DP23, P17612, Q13362 | CALM1, PRKACA, PPP2R5C | More | | Physostigmine | hsa04144 | Endocytosis | 4.07E-03 | 5 | Q9H444, O75351, P42566, Q15438, Q14161 | CHMP4B, VPS4B, EPS15, PSCD1, GIT2 | More | | Physostigmine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Physostigmine | hsa04217 | Necroptosis | 4.56E-03 | 4 | P23458, Q9NQC7, Q9H444, O75351 | JAK1, CYLD, CHMP4B, VPS4B | More | | Physostigmine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.50E-02 | 3 | P17612, Q13362, P0DP23 | PRKACA, PPP2R5C, CALM1 | More | | Physostigmine | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Physostigmine | hsa04613 | Neutrophil extracellular trap formation | 1.86E-02 | 14 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Physostigmine | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Physostigmine | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Physostigmine | hsa04640 | Hematopoietic cell lineage | 2.62E-03 | 14 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P09564, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF, IL1B | More | | Physostigmine | hsa04650 | Natural killer cell mediated cytotoxicity | 4.85E-04 | 13 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Physostigmine | hsa04657 | IL-17 signaling pathway | 1.56E-02 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Physostigmine | hsa04658 | Th1 and Th2 cell differentiation | 2.95E-05 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Physostigmine | hsa04659 | Th17 cell differentiation | 1.17E-04 | 14 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P01584, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, IL1B, CD3E, CD3G, CD247, JAK1 | More | | Physostigmine | hsa04660 | T cell receptor signaling pathway | 1.96E-04 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Physostigmine | hsa04713 | Circadian entrainment | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | | Physostigmine | hsa04720 | Long-term potentiation | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | | Physostigmine | hsa04728 | Dopaminergic synapse | 1.55E-02 | 3 | P17612, Q13362, P0DP23 | PRKACA, PPP2R5C, CALM1 | More | | Physostigmine | hsa04740 | Olfactory transduction | 6.71E-03 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | | Physostigmine | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.14E-04 | 11 | P14778, P01584, P51828, P22694, Q16539, P19174, P42338, Q14643, P24723, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ, CALM2 | More | | Physostigmine | hsa04910 | Insulin signaling pathway | 3.62E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | | Physostigmine | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Physostigmine | hsa04916 | Melanogenesis | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | | Physostigmine | hsa04921 | Oxytocin signaling pathway | 1.84E-02 | 3 | P0DP23, P17612, Q96RR4 | CALM1, PRKACA, CAMKK2 | More | | Physostigmine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Physostigmine | hsa04924 | Renin secretion | 1.09E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | | Physostigmine | hsa04970 | Salivary secretion | 2.20E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | | Physostigmine | hsa04971 | Gastric acid secretion | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | | Physostigmine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Physostigmine | hsa04976 | Bile secretion | 2.20E-02 | 2 | P17612, Q14032 | PRKACA, BAAT | More | | Physostigmine | hsa05031 | Amphetamine addiction | 2.87E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | | Physostigmine | hsa05034 | Alcoholism | 1.29E-02 | 3 | P17612, P0DP23, Q96RR4 | PRKACA, CALM1, CAMKK2 | More | | Physostigmine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Physostigmine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Physostigmine | hsa05140 | Leishmaniasis | 2.29E-02 | 9 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MAPK14, NCF4 | More | | Physostigmine | hsa05144 | Malaria | 2.43E-02 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Physostigmine | hsa05146 | Amoebiasis | 1.54E-04 | 13 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Physostigmine | hsa05150 | Staphylococcus aureus infection | 1.91E-02 | 4 | Q14532, P59665, P59666, P49913 | KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | Physostigmine | hsa05168 | Herpes simplex virus 1 infection | 4.79E-02 | 8 | P25963, Q07955, Q01130, Q9Y2A4, P51522, P17038, P52738, O75820 | NFKBIA, SFRS1, SFRS2, ZNF443, ZNF83, ZNF43, ZNF140, ZNF189 | More | | Physostigmine | hsa05202 | Transcriptional misregulation in cancer | 6.59E-03 | 15 | P17844, P14780, P27930, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | DDX5, MMP9, IL1R2, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Physostigmine | hsa05212 | Pancreatic cancer | 2.87E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | | Physostigmine | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Physostigmine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.58E-03 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Physostigmine | hsa05321 | Inflammatory bowel disease | 1.21E-02 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | |